Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum

This study has been withdrawn prior to enrollment.
(The sponsor stopped the study.)
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01153945
First received: June 29, 2010
Last updated: August 27, 2011
Last verified: August 2011
  Purpose

Much experimental data has suggested that thyroid hormones (T3 and T4) may modulate neoplastic cells and that T3/T4 deprivation may remove this stimulus. It is now well established that T3/T4 affects cell division/angiogenesis through binding to integrin avb3, commonly over-expressed on many cancer cells. In the experimental settings, mimicking hypothyroidism in the cells is a difficult task. Currently, the use of charcoal stripped serum is used. Using this method, the serum is stripped not only from T3 and T4, as intended, but also from central and important cytokines and growth factor. This leads to a reduced rate of cancer cell proliferation and thus, does not reflect the natural environment in which cancer cells residue under hypothyroid conditions.

The investigators aim to characterize and establish the effects of serum from hypothyroid patients on the proliferation/viability of a variety of cancer cell models.


Condition
Thyroid Cancer

Study Type: Observational
Official Title: Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum

Resource links provided by NLM:


Further study details as provided by Meir Medical Center:

Enrollment: 60
Study Start Date: February 2011
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Hypothyroid
Non hypothyroid
Healthy subjects

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Thyroid cancer patients before/after radioactive iodine total body scan or treatment admitted to the Endocrinology Institute, Meir Medical Center

Criteria

Inclusion Criteria:

  • Hypothyroid state

Exclusion Criteria:

  • Non hypothyroid state
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01153945

Locations
Israel
Meir Medical Center
Kfar-Saba, Israel
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Dan Nabriski, MD Meir Medical Center
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01153945     History of Changes
Other Study ID Numbers: 097-2010
Study First Received: June 29, 2010
Last Updated: August 27, 2011
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Hypothyroid and non hypothyroid

Additional relevant MeSH terms:
Thyroid Neoplasms
Thyroid Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 23, 2014